An increased risk of stroke among young schizophrenia patients

School of Health Care Administration, Taipei Medical University, Taipei 110, Taiwan.
Schizophrenia Research (Impact Factor: 4.43). 04/2008; 101(1-3):234-41. DOI: 10.1016/j.schres.2007.12.485
Source: PubMed

ABSTRACT This study sets out to estimate the risk of stroke developing among young schizophrenia patients during a five-year follow-up period after hospitalization for episodes of acute exacerbation.
Hospitalized schizophrenia patients under 45 years of age were identified from the Taiwan National Health Insurance Research Database for the year 1998 (n=5001). Two age-matched cases were randomly selected for each schizophrenia patient from among patients who underwent appendectomies in the same year (n=10,002). Each individual patient was retrospectively followed up from 1998 until the end of 2003 to determine whether any had developed strokes. Cox proportional hazard regressions were carried out to compute the adjusted five-year survival rate.
A total of 219 patients (1.46%) developed strokes during the five-year follow-up period, with the attacks occurring among 2.46% of schizophrenia patients and 0.94% of the comparison cohort. Following adjustment for patients' demographic characteristics, select comorbid medical disorders and substance abuse, schizophrenia patients were found to be 2.02 times (p<0.001) more likely to develop strokes during the follow-up period than age-matched appendectomy patients. The adjusted hazard ratios of developing stroke for male and female schizophrenia patients were, respectively, 1.64 (p<0.001) and 2.87 (p<0.001) times greater than their counterparts in the comparison group.
As compared with the comparison group, young schizophrenia patients demonstrated a two-fold increased risk of developing stroke during the five-year period after hospitalization. The risk of developing stroke among schizophrenia patients was found to be much higher for females than males.

Download full-text


Available from: Fei-Hsiu Hsiao, Jun 28, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to estimate the incidence and relative risk of stroke and post-stroke all-cause mortality in patients with schizophrenia. This study identified a study population from the National Health Insurance Research Database (NHIRD) between 1999 and 2003 that included 80,569 patients with schizophrenia and 241,707 age- and sex-matched control participants without schizophrenia. The participants were randomly selected from the 23,981,020-participant NHIRD, which consists of 96% Taiwanese participants. Participants who had experienced a stroke between 1999 and 2003 were excluded. Using data from the NHIRD between 2004 and 2008, the incidence of stroke (ICD-9-CM code 430-438) and patient survival after stroke were calculated for both groups. After adjusting for confounding risk factors, a Cox proportional-hazards model was used to compare the five-year stroke-free survival rate to the all-cause mortality rate across the two cohorts. Over five years, 1380 (1.71%) patients with schizophrenia and 2954 (1.22%) controls suffered from strokes. After adjusting for demographic characteristics and comorbid medical conditions, patients with schizophrenia were 1.13 times more likely to have a stroke (95% CI=1.05-1.22; P=0.0006). In addition, 1039 (24%) patients who had a stroke died during the follow-up period. After adjusting for patient, physician and hospital variables, the all-cause mortality hazard ratio for patients with schizophrenia was 1.23 (95% CI=1.06-1.41; P=0.0052). During a five-year follow-up, the likelihood of developing a stroke and the all-cause mortality rate were greater among patients with schizophrenia as compared with the control group.
    Schizophrenia Research 03/2012; 138(1):41-7. DOI:10.1016/j.schres.2012.02.013 · 4.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The health burden of antipsychotic medication is well known, but the disproportionate effect on women as compared with men is underappreciated. The goal of this article is preventive--to better inform clinicians so that the risks to women and to their offspring can be diminished. All PubMed sources in which the search term gender (or sex) was linked to a side effect of antipsychotic medication were reviewed. There is general agreement in the literature on women's increased susceptibility to weight gain, diabetes, and specific cardiovascular risks of antipsychotics, with less consensus on malignancy risks and risks to the fetus. Cardiovascular death, to which men are more susceptible than women, is disproportionately increased in women by the use of antipsychotics. Sedating antipsychotics raise the risk of embolic phenomena during pregnancy, and postpartum. Prolactin-elevating drugs suppress gonadal hormone secretion and may enhance autoimmune proclivity. Clinicians need to be aware of the differential harm that women (and their offspring) can incur from the side effects of antipsychotics.
    Schizophrenia Bulletin 05/2008; 35(5):937-48. DOI:10.1093/schbul/sbn023 · 8.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although a body of evidence indicates a link between psychiatric illnesses and allergies, no one has investigated the association between schizophrenia and atopic disorders. The objective of this nationwide population-based study was to examine the prevalence and risk of atopic disorders (asthma, allergic rhinitis, urticaria, and atopic dermatitis) among schizophrenia patients. This study used data from the Taiwan National Health Insurance Research Database covering the years 2000 to 2002. A total of 44,187 patients diagnosed with schizophrenia in the year 2000 were included, together with 132,561 matched non-psychiatric controls. Follow up until the end of 2002 identified concurrent diagnoses of atopic disorders. Logistic regression analyses were performed after controlling for the covariates of socio-demographic characteristics. Findings indicated high comorbidity, with 20.2% of schizophrenia patients (approximately one in five) experiencing concurrent atopic disorders. Moreover, schizophrenia in patients was independently associated with a 1.3-fold increased risk (95%CI=1.24-1.39) of concurrent asthma, after adjusting for socio-demographic characteristics. Yet the risk of diagnosed allergic rhinitis and urticaria was 23% (95%CI=0.74-0.81) and 26% (95%CI=0.72-0.77) lower, respectively, among schizophrenia patients compared to people without any psychiatric disease. Data suggests an increased risk of asthma and decreased risk of allergic rhinitis and urticaria among schizophrenia patients. Future studies on the identification of common etiologic pathways for schizophrenia and asthma could be significant for developing innovative treatments that target both illnesses concurrently.
    Schizophrenia Research 02/2009; 108(1-3):191-6. DOI:10.1016/j.schres.2008.12.021 · 4.43 Impact Factor